C4XD receives $10 million upfront, potential milestones totalling $284 million plus royalties
29 March 2018 – C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, today announces that it has signed a licensing agreement with Indivior UK Limited (LON: INDV, "Indivior") to further develop and commercialise C4XD’s oral Orexin-1 receptor antagonist ("C4X3256") for the treatment of addiction. C4X3256 aims to treat addiction by targeting the "craving" process itself and, therefore, can be applied across a broad range of substance use disorders. The treatment of addiction represents a substantial area of unmet medical need, forecast to be worth an estimated $13 billion per annum in 20181.
Shares in U.K. biotech C4X Discovery almost doubled today after Reckitt Benkiser spinout Indivior agreed to a $294 million deal for a drug candidate to treat addiction.
Indivior is paying $10 million upfront for global rights to C4X3256, an orexin-1 (OX1) receptor antagonist in preclinical development that C4XD said has potential in just about any form of addiction—including tobacco, opioid analgesic and alcohol—as it targets the feeling of craving itself...
Industries collide, collaborate at Build: London 2017
The company’s 4Sight project pioneers the creation of a specialised visualiser to allow its research scientists to view, understand and interrogate the complex, multidimensional molecular shape data of drug molecules. Having measured these shapes using the company’s proprietary Conformetrix technology, this “4D molecular data” can then be visualised and manipulated to inspire the design of drug molecules in new and innovative ways. Working from both a desktop environment and within a VR space, the visualiser also facilitates simultaneous collaboration with multiple stakeholders across various sites.
“4Sight allows users to see the results of an experiment and a view of drug molecules in ways that have never before been possible”, as C4X’s Chief Scientific Officer Craig Fox explains.
Clive Dix, chief executive of C4X Discovery Holdings plc, (LON:C4XD) brings Proactive up to speed on developments with the firm's portfolio of drug candidates.
They've recently presented some pre-clinical data at a leading industry conference which they say strengthens the evidence base backing the potential of the anti-addiction drug Orexin-1. It's being developed to target the craving process and therefore is expected to be used across a broad range of substance disorders. The latest study assessed nicotine self-administration and cue-induced reinstatement; the latter is where strong cravings are triggered by an object or ritual closely associated with taking an addictive substance.
Programme demonstrates potential application across a broad range of substance use disorders
13 November 2017 – C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, presented new pre-clinical data on its Orexin-1 antagonist programme at Neuroscience 2017 on 11th November 2017 in Washington, DC.
Bhavna is building the commercial team having, together with the CEO, re-shaped the company’s strategy, and supported the recent £7 million raise. Bhavna is establishing collaborations with international organisations to harness the best drug discovery capabilities for the development of new treatments. She is also developing alliances with UK non-profit organisations to maximise the impact of intellectual value developed by academics and in-house at C4X.